Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense. Its lead product candidate is Tonmyar (TNX-102 SL), a proprietary low-dose cyclobenzaprine and sublingual tablet as a bedtime administration, which is in Phase III development for the treatment of posttraumatic stress disorder (PTSD) and Fibromyalgia; and Phase II development for the treatment of agitation in Alzheimer's disease.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone212-980-9155
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees12
Next Earnings Date11/8/2019 (Estimated)
OptionableOptionable
Tonix Pharmaceuticals (NASDAQ:TNXP) Frequently Asked Questions
What is Tonix Pharmaceuticals' stock symbol?
Tonix Pharmaceuticals trades on the NASDAQ under the ticker symbol "TNXP."
When did Tonix Pharmaceuticals' stock split? How did Tonix Pharmaceuticals' stock split work?
Tonix Pharmaceuticals shares reverse split before market open on Wednesday, November 28th 2018. The 1-10 reverse split was announced on Tuesday, November 27th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 27th 2018. An investor that had 100 shares of Tonix Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.
How were Tonix Pharmaceuticals' earnings last quarter?
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) announced its quarterly earnings data on Monday, August, 12th. The company reported ($0.95) earnings per share for the quarter, beating analysts' consensus estimates of ($0.96) by $0.01. View Tonix Pharmaceuticals' Earnings History.
When is Tonix Pharmaceuticals' next earnings date?
What price target have analysts set for TNXP?
1 Wall Street analysts have issued 12-month price targets for Tonix Pharmaceuticals' shares. Their forecasts range from $1.30 to $1.30. On average, they expect Tonix Pharmaceuticals' stock price to reach $1.30 in the next twelve months. This suggests a possible upside of 233.7% from the stock's current price. View Analyst Price Targets for Tonix Pharmaceuticals.
What is the consensus analysts' recommendation for Tonix Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tonix Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tonix Pharmaceuticals.
Has Tonix Pharmaceuticals been receiving favorable news coverage?
News articles about TNXP stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Tonix Pharmaceuticals earned a news impact score of -1.7 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Tonix Pharmaceuticals.
Who are some of Tonix Pharmaceuticals' key competitors?
Some companies that are related to Tonix Pharmaceuticals include Ceapro (CRPOF), Intec Pharma (NTEC), OncoSec Medical (ONCS), Acerus Pharmaceuticals (TRLPF), Provectus Biopharmaceuticals (PVCT), ProPhase Labs (PRPH), Mateon Therapeutics (MATN), Aytu Bioscience (AYTU), Cassava Sciences (SAVA), AEterna Zentaris (AEZS), BIOLINERX LTD/S (BLRX), Seelos Therapeutics (SEEL), Aerpio Pharmaceuticals (ARPO), RegeneRx Biopharmaceuticals (RGRX) and AzurRx BioPharma (AZRX).
What other stocks do shareholders of Tonix Pharmaceuticals own?
Who are Tonix Pharmaceuticals' key executives?
Tonix Pharmaceuticals' management team includes the folowing people:
- Dr. Seth Lederman, Co-Founder, Pres, CEO & Chairman (Age 61)
- Mr. Bradley Saenger, CFO & Treasurer (Age 45)
- Dr. Gregory M. Sullivan, Chief Medical Officer & Sec. (Age 53)
- Mrs. Jessica Edgar Morris, Chief Operating Officer
- Dr. Ronald R. Notvest Ph.D., MBA, Exec. VP of Commercial Planning and Devel.
How do I buy shares of Tonix Pharmaceuticals?
Shares of TNXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Tonix Pharmaceuticals' stock price today?
One share of TNXP stock can currently be purchased for approximately $0.39.
How big of a company is Tonix Pharmaceuticals?
Tonix Pharmaceuticals has a market capitalization of $6.12 million. The company earns $-26,090,000.00 in net income (profit) each year or ($26.81) on an earnings per share basis. Tonix Pharmaceuticals employs 12 workers across the globe.View Additional Information About Tonix Pharmaceuticals.
What is Tonix Pharmaceuticals' official website?
How can I contact Tonix Pharmaceuticals?
Tonix Pharmaceuticals' mailing address is 509 MADISON AVENUE SUITE 1608, NEW YORK NY, 10022. The company can be reached via phone at 212-980-9155 or via email at [email protected]
MarketBeat Community Rating for Tonix Pharmaceuticals (NASDAQ TNXP)
MarketBeat's community ratings are surveys of what our community members think about Tonix Pharmaceuticals and other stocks. Vote "Outperform" if you believe TNXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TNXP will underperform the S&P 500 over the long term. You may vote once every thirty days.
